ESR1 and triple-negative breast carcinoma: In contrast to liraglutide’s effects in estrogen receptor-positive breast cancer, a recent in vitro study observed that liraglutide stimulates the growth of triple-negative breast cancer cells (Shadboorestan et al., 2021).